Cardiovasc Prev Pharmacother.  2025 Jan;7(1):13-20. 10.36011/cpp.2025.7.e1.

Pharmacological management of diabetes in older adults

• Noh J

• KMID: 2564012
• DOI: http://doi.org/10.36011/cpp.2025.7.e1

Abstract

As the global population continues to age, the rising prevalence of diabetes among older adults has become a significant public health concern. Consequently, effective and safe management of diabetes mellitus in this population is an increasingly critical focus in clinical practice. Older patients present considerable variability in functional status, with many experiencing physical disabilities, visual impairments, cognitive decline, or psychological conditions such as depression. Therefore, individualized treatment strategies that consider the presence and progression of geriatric syndromes, comorbidities, and the risk of hypoglycemia are essential for optimizing the pharmacological management of diabetes in older adults.

Keyword

Diabetes mellitus; Aged; Hypoglycemic agents

Reference

1. Moon JS, Kang S, Choi JH, Lee KA, Moon JH, Chon S, et al. 2023 Clinical Practice Guidelines for diabetes management in Korea: full version recommendation of the Korean Diabetes Association. Diabetes Metab J. 2024; 48:546–708. DOI: 10.4093/dmj.2024.0249. PMID: 39091005.

2. Alagiakrishnan K, Sclater A. Psychiatric disorders presenting in the elderly with type 2 diabetes mellitus. Am J Geriatr Psychiatry. 2012; 20:645–52. DOI: 10.1097/jgp.0b013e31823038db. PMID: 21989315.

3. Ponticelli C, Sala G, Glassock RJ. Drug management in the elderly adult with chronic kidney disease: a review for the primary care physician. Mayo Clin Proc. 2015; 90:633–45. DOI: 10.1016/j.mayocp.2015.01.016. PMID: 25771152.

4. Wong CW. Avoiding hypoglycaemia: a new target of care for elderly diabetic patients. Hong Kong Med J. 2015; 21:444–54. DOI: 10.12809/hkmj144494. PMID: 26044870.

5. Lipska KJ, Ross JS, Wang Y, Inzucchi SE, Minges K, Karter AJ, et al. National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. JAMA Intern Med. 2014; 174:1116–24. DOI: 10.1001/jamainternmed.2014.1824. PMID: 24838229.

6. Yang SW, Park KH, Zhou YJ. The impact of hypoglycemia on the cardiovascular system: physiology and pathophysiology. Angiology. 2016; 67:802–9. DOI: 10.1177/0003319715623400. PMID: 26685181.

7. Davis SN, Duckworth W, Emanuele N, Hayward RA, Wiitala WL, Thottapurathu L, et al. Effects of severe hypoglycemia on cardiovascular outcomes and death in the Veterans Affairs Diabetes Trial. Diabetes Care. 2019; 42:157–63. DOI: 10.2337/dc18-1144. PMID: 30455335.

8. Zhao Y, Kachroo S, Kawabata H, Colilla S, Mukherjee J, Fonseca V, et al. Association between hypoglycemia and fall-related fractures and health care utilization in older veterans with type 2 diabetes. Endocr Pract. 2016; 22:196–204. DOI: 10.4158/ep15640.or. PMID: 26492544.

9. Ye M, Yang Q, Zhang L, Song H, Fu Q, Qian J, et al. Effect of hypoglycemic events on cognitive function in individuals with type 2 diabetes mellitus: a dose-response meta-analysis. Front Neurol. 2024; 15:1394499. DOI: 10.3389/fneur.2024.1394499. PMID: 39193149.

10. Ko SH, Ko SH, Ahn YB, Song KH, Han KD, Park YM, et al. Association of vitamin B12 deficiency and metformin use in patients with type 2 diabetes. J Korean Med Sci. 2014; 29:965–72. DOI: 10.3346/jkms.2014.29.7.965. PMID: 25045229.

11. Yang W, Cai X, Wu H, Ji L. Associations between metformin use and vitamin B12 levels, anemia, and neuropathy in patients with diabetes: a meta-analysis. J Diabetes. 2019; 11:729–43. DOI: 10.1111/1753-0407.12900. PMID: 30615306.

12. Leung S, Mattman A, Snyder F, Kassam R, Meneilly G, Nexo E. Metformin induces reductions in plasma cobalamin and haptocorrin bound cobalamin levels in elderly diabetic patients. Clin Biochem. 2010; 43:759–60. DOI: 10.1016/j.clinbiochem.2010.02.011.

13. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355:2427–43. DOI: 10.1056/nejmoa066224. PMID: 17145742.

14. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009; 180:32–9. DOI: 10.1503/cmaj.080486. PMID: 19073651.

15. Schwartz AV, Chen H, Ambrosius WT, Sood A, Josse RG, Bonds DE, et al. Effects of TZD use and discontinuation on fracture rates in ACCORD Bone Study. J Clin Endocrinol Metab. 2015; 100:4059–66. DOI: 10.1210/jc.2015-1215. PMID: 26305617.

16. Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004; 34:535–42. DOI: 10.1111/j.1365-2362.2004.01381.x.

17. Del Prato S, Heine RJ, Keilson L, Guitard C, Shen SG, Emmons RP. Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis. Diabetes Care. 2003; 26:2075–80. DOI: 10.2337/diacare.26.7.2075. PMID: 12832316.

18. Papa G, Fedele V, Rizzo MR, Fioravanti M, Leotta C, Solerte SB, et al. Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: a randomized, open-label, two-period, cross-over trial. Diabetes Care. 2006; 29:1918–20. DOI: 10.2337/dc05-2495. PMID: 16873803.

19. Schernthaner G, Barnett AH, Patel S, Hehnke U, von Eynatten M, Woerle HJ. Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years. Diabetes Obes Metab. 2014; 16:1078–86. DOI: 10.1111/dom.12321. PMID: 24865132.

20. Round EM, Engel SS, Golm GT, Davies MJ, Kaufman KD, Goldstein BJ. Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies. Drugs Aging. 2014; 31:203–14. DOI: 10.1007/s40266-014-0155-7.

21. Karyekar CS, Ravichandran S, Allen E, Fleming D, Frederich R. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus. Clin Interv Aging. 2013; 8:419–30. DOI: 10.2147/cia.s41246. PMID: 23626461.

22. Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother. 2010; 8:405–18. DOI: 10.1016/j.amjopharm.2010.10.003. PMID: 21335294.

23. Leiter LA, Teoh H, Braunwald E, Mosenzon O, Cahn A, Kumar KM, et al. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care. 2015; 38:1145–53. DOI: 10.2337/dc14-2868. PMID: 25758769.

24. Bode BW, Brett J, Falahati A, Pratley RE. Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies. Am J Geriatr Pharmacother. 2011; 9:423–33. DOI: 10.1016/j.amjopharm.2011.09.007. PMID: 22055210.

25. Boustani MA, Pittman I 4th, Yu M, Thieu VT, Varnado OJ, Juneja R. Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years. Diabetes Obes Metab. 2016; 18:820–8. DOI: 10.1111/dom.12687. PMID: 27161178.

26. Meneilly GS, Roy-Duval C, Alawi H, Dailey G, Bellido D, Trescoli C, et al. Lixisenatide therapy in older patients with type 2 diabetes inadequately controlled on their current antidiabetic treatment: the GetGoal-O randomized trial. Diabetes Care. 2017; 40:485–93. DOI: 10.2337/dc16-2143. PMID: 28188240.

27. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375:311–22. DOI: 10.1056/nejmoa1603827.

28. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375:1834–44. DOI: 10.1056/nejmoa1607141. PMID: 27633186.

29. Johnston PS, Lebovitz HE, Coniff RF, Simonson DC, Raskin P, Munera CL. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab. 1998; 83:1515–22. PMID: 9589648.

30. Josse RG, Chiasson JL, Ryan EA, Lau DC, Ross SA, Yale JF, et al. Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Res Clin Pract. 2003; 59:37–42. DOI: 10.1016/s0168-8227(02)00176-6. PMID: 12482640.

31. Sinclair AJ, Bode B, Harris S, Vijapurkar U, Shaw W, Desai M, et al. Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: a pooled analysis. J Am Geriatr Soc. 2016; 64:543–52. DOI: 10.1111/jgs.14028.

32. Lunati ME, Cimino V, Gandolfi A, Trevisan M, Montefusco L, Pastore I, et al. SGLT2-inhibitors are effective and safe in the elderly: the SOLD study. Pharmacol Res. 2022; 183:106396. DOI: 10.1016/j.phrs.2022.106396. PMID: 35970329.

33. Fioretto P, Mansfield TA, Ptaszynska A, Yavin Y, Johnsson E, Parikh S. Long-term safety of dapagliflozin in older patients with type 2 diabetes mellitus: a pooled analysis of phase IIb/III studies. Drugs Aging. 2016; 33:511–22. DOI: 10.1007/s40266-016-0382-1. PMID: 27357173.

34. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373:2117–28. DOI: 10.1056/nejmoa1504720. PMID: 26378978.

35. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377:644–57. DOI: 10.1056/nejmoa1611925.

36. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380:347–57. DOI: 10.1056/nejmoa1812389.

37. Pratley RE, Cannon CP, Cherney DZ, Cosentino F, McGuire DK, Essex MN, et al. Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. Lancet Healthy Longev. 2023; 4:e143–54. DOI: 10.1016/s2666-7568(23)00032-6. PMID: 37003273.

38. Jeon JY, Kim DJ. Benefit and safety of sodium-glucose co-transporter 2 inhibitors in older patients with type 2 diabetes mellitus. Diabetes Metab J. 2024; 48:837–46. DOI: 10.4093/dmj.2024.0317. PMID: 39313229.

39. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015; 38:1680–6. DOI: 10.2337/dc15-1251. PMID: 26203064.

40. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015; 38:1687–93. DOI: 10.2337/dc15-0843. PMID: 26078479.

41. Rigato M, Fadini GP, Avogaro A. Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2023; 25:2963–9. DOI: 10.1111/dom.15193. PMID: 37402697.

42. Yabe D, Shiki K, Suzaki K, Meinicke T, Kotobuki Y, Nishida K, et al. Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes. BMJ Open. 2021; 11:e045844. DOI: 10.1136/bmjopen-2020-045844. PMID: 33827843.

43. American Diabetes Association Professional Practice Committee. 13. Older adults: standards of care in diabetes: 2025. Diabetes Care. 2025; 48(Supplement_1):S266–82.

44. Trimble LA, Sundberg S, Markham L, Janicijevic S, Beattie BL, Meneilly GS. Value of the clock drawing test to predict problems with insulin skills in older adults. Can J Diabetes. 2005; 29:102–4.

45. Zeyfang A, Berndt S, Aurnhammer G, Nikolaus T, Oster P, Bahrmann A. A short easy test can detect ability for autonomous insulin injection by the elderly with diabetes mellitus. J Am Med Dir Assoc. 2012; 13:81. DOI: 10.1016/j.jamda.2010.10.006. PMID: 21450217.

46. Ritzel R, Roussel R, Bolli GB, Vinet L, Brulle-Wohlhueter C, Glezer S, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015; 17:859–67. DOI: 10.1111/dom.12485. PMID: 25929311.

47. Sorli C, Warren M, Oyer D, Mersebach H, Johansen T, Gough SC. Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials. Drugs Aging. 2013; 30:1009–18. DOI: 10.1007/s40266-013-0128-2. PMID: 24170235.